NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
Clinical Trials
5 trialsNCT00550277 2021-11-23
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT00663832 2020-12-19
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
Novartis
Phase 1 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed